9/5/2013 9:52:02 AM
STOCKHOLM, 5 September 2013 – The collaboration between Karo Bio AB and Pfizer
Inc. has successfully resulted in a significant achievement within the RORgamma
project triggering the first milestone payment to Karo Bio. The purpose of the
collaboration is to develop drugs for treatment of autoimmune diseases.
“The teams from Karo Bio and Pfizer have enjoyed an excellent interaction and
relationship which has helped meet this goal. This achievement clearly
demonstrates the value Karo Bio brings to its partners in the area of nuclear
receptor drug discovery”, says Karo Bio’s CEO Per Bengtsson.
Help employers find you! Check out all the jobs and post your resume.
comments powered by